SELECTION OF A RADIOPHARMACEUTICAL DRUG FOR POSITRON EMISSION TOMOGRAPHY OF THE MYOCARDIAL FOR PLANNING CORONARY INTERVENTIONS

A study comparing the effectiveness of 18-fluorodeoxyglucose and rubidium-82 in positron emission tomography for planning coronary interventions was carried out. 37 PET studies with 18-FDG were performed in patients with complaints of angina pectoris, previously identified atherosclerotic vascular changes, coronary intervention for a history of ischemic heart disease or myocardial infarction. As a result, 3 patients were found to have defects in FDG metabolism corresponding to cicatricial changes in the background of a previous myocardial infarction. After examination, a representative group of 11 patients was selected for PET with rubidium-82. According to the results of the study, one patient had a myocardial perfusion defect corresponding to the FDG ametabolism zone. In two patients, the study in exercise revealed a defect in myocardial perfusion, which was not previously determined. Subsequent coronary angiography confirmed the presence of hemodynamically significant stenosis of the anterior interventricular branch of the left coronary artery, in the basin of which a perfusion defect was detected. The results obtained make it possible to diagnose the presence of incoming myocardial ischemia in a patient. The study revealed the advantages of PET with rubidium-82 over PET with 18-FDG when planning coronary interventions. Keywords. positron emission tomography, PET, radiology, 18-fluorodeoxyglucose, rubidium chloride-82.